RAPT Therapeutics Inc.

1.17
-0.05 (-4.10%)
At close: Jan 23, 2025, 3:59 PM
1.25
6.84%
Pre-market Jan 24, 2025, 05:09 AM EST
-4.10%
Bid 1.18
Market Cap 40.90M
Revenue (ttm) 4.75M
Net Income (ttm) -96.59M
EPS (ttm) -2.78
PE Ratio (ttm) -0.42
Forward PE -0.92
Analyst Hold
Ask 1.26
Volume 1,413,653
Avg. Volume (20D) 3,537,970
Open 1.22
Previous Close 1.22
Day's Range 1.15 - 1.24
52-Week Range 0.79 - 27.35
Beta 0.32

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2019
Employees 70
Stock Exchange NASDAQ
Ticker Symbol RAPT

Analyst Forecast

According to 10 analyst ratings, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 241.88% from the latest price.

Buy 30.00%
Hold 60.00%
Sell 10.00%
Stock Forecasts
1 month ago
+110.81%
RAPT Therapeutics shares are trading higher after ... Unlock content with Pro Subscription
2 months ago
-39.45%
RAPT Therapeutics shares are trading lower after the company terminated its Zelnecirnon program following an FDA clinical hold due to a severe adverse event involving liver injury.